Poland's Mabion surges on commercial production deal with Novavax

Mabion SA

08/10/2021 08:23

** Shares in Polish biotech company Mabion  MABP.WA  jump
24%, paring earlier gains of as much as almost 47%, after
company signs $372 million commercial scale production deal with
Novavax  NVAX.O 
    ** Under the deal, Mabion will produce the antigene for the
Novavax COVID-19 vaccine, with commercial scale production
starting in December  urn:newsml:reuters.com:*:nFWN2R31EW
    ** The shares are on track for their best day since striking
the initial cooperation deal with Novavax in March  urn:newsml:reuters.com:*:nL2N2L10PM
    ** Mabion's shares are up over 360% YTD
    

 (Reporting by Karol Badohal)
 ((karl.badohal@thomsonreuters.com; +48 58 769 65 97))